Skip to main content
TipRanks
Go Ultimate75% OFF

CalciMedica (CALC) Stock Price & Analysis

319 Followers

CALC Stock Chart & Stats

$1.21-$0.01(-0.82%)
At close: 4:00 PM EST
$1$2$3Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$1.19 - $1.31
52-Week Range
$1.00 - $36.00
Previous Close
$1.22
Volume
N/A
Average Volume (3M)
77.92K
Market Cap
$8.34M
Enterprise Value
$4.33M
Total Cash (Recent Filing)
$13.77M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
0.13
Next Earnings
Apr 01, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

The absence of debt reduces near-term interest and refinancing pressure, while positive equity provides some balance-sheet support for ongoing development. This gives CalciMedica greater financial flexibility than a similarly loss-making biotech carrying material leverage.

Nasdaq Compliance Restored

Restored Nasdaq compliance removes the immediate listing deficiency and reduces operational disruption associated with potential delisting. Maintaining an exchange listing can preserve access to public capital markets and support the company’s ability to finance clinical development.

Losses Have Narrowed

Narrower losses indicate some improvement in the company’s cost or spending profile, even though profitability remains distant. If sustained, this trend could extend the cash runway and reduce the amount of external funding required before potential product revenue.

Bears Say

No Commercial Revenue

The absence of commercial revenue leaves CalciMedica dependent on successful clinical and regulatory progress before it can become self-funding. Continued operating losses also make future earnings uncertain and increase the financial consequences of delays or unsuccessful development.

Substantial Cash Burn

Persistent negative operating and free cash flow means the business is consuming capital rather than generating funds internally. This limits financial durability and requires continued access to financing, particularly while clinical development and regulatory activities remain ongoing.

Equity Funding And Dilution Risk

The planned equity-raising capacity can support liquidity and corporate activities, but issuing shares or share-linked securities may dilute existing ownership. Reliance on these financings also underscores the company’s dependence on external capital while revenue remains absent.

CalciMedica News

CALC FAQ

What was CalciMedica’s price range in the past 12 months?
CalciMedica lowest stock price was $1.00 and its highest was $36.00 in the past 12 months.
What is CalciMedica’s market cap?
CalciMedica’s market cap is $8.34M.
When is CalciMedica’s upcoming earnings report date?
CalciMedica’s next earnings report is estimated for Apr 01, 2027 (not yet confirmed), which is in 136 days.
How were CalciMedica’s earnings last quarter?
CalciMedica released its earnings results on Nov 10, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$1.275 by $1.035.
Is CalciMedica overvalued?
According to Wall Street analysts CalciMedica’s price is currently Undervalued.
Does CalciMedica pay dividends?
CalciMedica does not currently pay dividends.
What is CalciMedica’s EPS estimate?
CalciMedica’s EPS estimate is -0.63.
How many shares outstanding does CalciMedica have?
CalciMedica has 6,895,149 shares outstanding.
What happened to CalciMedica’s price movement after its last earnings report?
CalciMedica reported an EPS of -$0.24 in its last earnings report, beating expectations of -$1.275. Following the earnings report the stock price went down -9.571%.
Which hedge fund is a major shareholder of CalciMedica?
Hedge funds hold CalciMedica shares: the largest hedge-fund position in CalciMedica is 72,395,040 shares, and hedge funds increased their holdings by 498.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology